- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Gene Therapy for Arthritis
17 April 1998 8:00 pm
Scientists have used gene therapy to sharply reduce joint swelling from arthritis in rabbits. The finding, reported in this week's Proceedings of the National Academy of Sciences, could someday lead to a novel treatment for inflamed joints in people.
In arthritic joints, immune cells cause neighboring tissue to release proteins that trigger swelling, tissue degradation, and pain. Attempts to block these molecular signals--called IL-1 and TNF-a--have unpleasant side effects, such as broad immune suppression. Paul Robbins, a molecular geneticist at the University of Pittsburgh Medical School, thought that if he could get local cells to produce free-floating receptors for IL-1 or TNF-a, they could mop up excess molecules in the joint.
Robbins and his colleagues altered adenoviruses to carry IL-1 and TNF-a soluble receptor genes. Next they injected into the knees of arthritic rabbits adenovirus expressing either IL-1 receptor, TNF-a receptor, both receptors, or a control protein. Rabbits that received just the TNF-a showed little improvement relative to the control. However, those that received either IL-1 alone or with TNF-a had up to 85% fewer white blood cells and 65% less cartilage erosion in the injected knee.
To Robbins' surprise, the uninjected knees of the IL-1-treated rabbits also improved. "At first I thought the postdoc had screwed up," he says. To double-check, the group injected adenovirus carrying the luciferase gene, which makes a protein that glows and can easily be spotted. They found luciferase protein in white blood cells of the uninjected knee. Robbins thinks the white blood cells might ferry therapeutic genes to other inflamed joints. Gene therapy could be a good option for arthritis patients because all joints could be treated with a single injection, says Robbins.
"I am very excited about this work," says Susana Serrate-Sztein, director of the rheumatology branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland. Delivering more than one gene is a useful feature, she says, since arthritis can be caused by several immune proteins. Robbins points out, however, that adenovirus may not be a good gene carrier in people because the virus itself causes inflammation.